

Primary Percutaneous Coronary Intervention (PPCI) in Acute Myocardial Infarction Complicated by Cardiogenic Shock in a Newly Emerging Cardiac Centre in Nepal

Maskey A*, Regmi SR*, Bhatt Y*, Malla R*, Rajbhandari R*, Sharma D*, K.C. MB*, Limbu YR*, Dhamala L*

*Shahid Gangalal National Heart Centre, Kathmandu.

Corresponding: Dr. Arun Maskey

Shahid gangalal National Heart Centre, Bansbari, Kathmandu, Nepal, Tel: 00977-1-4371322, 00977-1-4371374, Fax 00977-1-4371123, Email: maskeyarun@yahoo.com

Abstract

Background: Acute myocardial infarction (AMI) is complicated by cardiogenic shock in 5-10% of patients. Mortality rate is exceedingly high and reaches 70-80% in those treated conservatively. Large thrombolytic trials demonstrate 60% mortality with most effective thrombolytic agent. In between September 2005 to August 2008 total PCI in Shahid gangalal National Heart Centre (SGNHC) Nepal was 452. among them primary PCI (PPCI) in AMI with cardiogenic shock was done in only 16 patients. In AMI with cardiogenic shock who underwent PPCI, 6 patients are in out of 50% (n=8) patients with cardiogenic shock who underwent PPCI, 6 patients are in routine follow up over 12 months and 2 were doing well in subsequent 6 months but lost in follow up afterwards. Primary PCI in AMI complicated by cardiogenic shock has lower mortality and improved outcome. High cost, high in-hospital mortality, need for trained manpower are the major limitations.

Keywords : Primary Percutaneous coronary intervention, myocardial infarction, cardio genic shock, SGNHC (Shahid Gangalal National Heart Centre)

INTRODUCTION

Cardiogenic shock is the commonest cause of death in patients with acute myocardial infarction (AMI) who reach hospital alive. Cardiogenic shock in AMI occurs in 40% or more of the left ventricle is destroyed. It is a result of onset of infarction due to massive necrosis and infarction. A relatively small infarction superimposed on extensive previous damage may precipitate cardiogenic shock. Acute myocardial infarction complicated by cardiogenic shock in 7-10 % of patients. Mortality rate is exceedingly high and reaches 70-80% in those treated conservatively. Large thrombolytic trials demonstrate 60% mortality with most effective thrombolytic agent. Comparison of 30 day mortality in AMI with cardiogenic shock with AMI between Reteplase or Alteplase, 50% of patients treated with Reteplase and 58% treated with Alteplase within 30 days (p=0.59).

An emerging trend has been to go for more aggressive therapeutic strategies early in patients who have cardiogenic shock following acute myocardial infarction. In the recent guidelines of the European Society and American College of Cardiology (ACC) and the American Heart Association (AHA) early mechanical revascularization for cardiogenic shock for patients younger than 75 years with ST-elevation AMI or left bundle-branch block.

Invasive strategy in developing country like Nepal is not only costly but also technically demanding. No study has been done till date with aggressive invasive strategy in poor

developing country like Nepal and hence its usefulness, justification and feasibility is not known. The purpose of this study was to evaluate the in-hospital mortality rate in a cohort of unselected consecutive patients with AMI complicated by cardiogenic shock treated with PPCI in SGNHC, the only national heart centre which offers this facility in Nepal.

METHODS

Sixteen consecutive patients who presented to SGNHC with ST elevation MI complicated by cardiogenic shock were studied. Those patients who presented with ST elevation MI with cardiogenic shock and mechanical complications like papillary muscle rupture, ventricular septal defect and free wall rupture in echocardiography were not considered for PPCI due to surgical indication. We do not have exact data of the whole incidence of cardiogenic shock in ST elevation MI. however, it is estimated to be approximately 5-7%. Diagnosis of acute ST elevation with cardiogenic shock was defined as evidence of hypo-perfusion (cold clammy skin, cerebral obtundation), systolic blood pressure <90 mm Hg, pulse >100 bpm and evidence of acute STEMI or new onset LBBB (ischemic chest pain and ST elevation in ECG).

This is a retrospective study between September 2005 to August 2008. Total PCI in SGNHC was done in 452 patients. Among them PPCI in AMI with cardiogenic shock was done in only 16 patients (3.5%).

RESULTS

Clinical characteristics of the patients included in this study are shown in table 1. The interval between AMI to Cardiogenic shock PPCI was 6-30 hours. The age range was between 21-77 yrs (mean 48.5±/16.52 yrs). There were 12 male and 4 female patients. The risk factors distribution showed diabetes in 4, smoking in 7, hypertension in 4 and strong family history in 2 patients. The baseline left ventricular ejection fraction (LVEF) by echocardiography was 30-41% (35.57 ±/ 3.92). The culprit vessels were 7 right coronary arteries (RCA), 6 left anterior descending arteries (LAD), 2 left circumflex (LCX) and 1 left main vessel (LM). Thrombolysis in myocardial infarction (TIMI) flow among 16 patients showed pre procedure TIMI flow 0 in 14 patients and TIMI flow 1 in 2 patients. Post procedural TIMI flow 3 was achieved in 13 patients. Intraaortic balloon pump (IABP) was used in 7 patients.

Characteristics	n=16
Mean Age (years)	48.5 ± 16.5
Male Sex	12 (75%)
Anterior MI	7 (44%)
Non anterior MI	9 (56%)
Diabetes Mellitus	4 (25%)
Hypertension	4 (25%)
Current Smoking	7 (44%)
Hyperlipidemia	3(19%)
IABP usage	7 (44%)
LVEF	35.6 ± 3.9%

Among those 16 patients with anterior ST elevation MI complicated by cardiogenic shock who underwent PPCI, 8 patients died in-hospital and 8 survived and were discharged. Of 8 deaths, culprit vessel could not be opened in 1 patient. 1 died due to pre-existing renal failure. 6 patients died despite opening the culprit vessel due to ongoing ischemia. Of the 8 patients who are alive, 6 are in routine follow up over 12 months and 2 are in routine follow up for subsequent 6 months.

DISCUSSION

Meta-analysis of 33 large randomized trial have shown that primary PCI is superior to thrombolysis for immediate treatment of ST-EMI due to more effective restoration of coronary artery, less recurrent myocardial ischemia, less secondary myocardial infarction, improved residual LV function and better clinical outcome including stroke.

The mortality in this study with 16 patients showed to be 50%. The causes of mortality were pre-existing renal failure, delayed procedural time.

The landmark Shock trial showed that early revascularization is better than medical management in AMI with cardiogenic shock. Thirty day survival was 54% and one year survival was 50%. Thirty day survival after successful PCI was 65% and after unsuccessful PCI was 20%. Mortality was related to TIMI flow. Mortality with TIMI grade flow showed TIMI 3 flow (mortality 98%) TIMI 2 flow (mortality 55%) and TIMI 1 or 0 flow (mortality 100%). The independent predictors of mortality in shock trial was increasing age, lower

systolic blood pressure, increasing age, lower systolic blood pressure, increasing time of randomization, lower post PCI TIMI flow 0/1, and multivessel PCI.

In a prospective randomized trial, 1333 patients at 80 centres in Germany between 1994 - 2001 in ALKK PCI registry 14.2% patients with AMI presented with cardiogenic shock. The in-hospital mortality was 46.1%. predictors for in-hospital mortality was post procedural TIMI flow 0/1, advanced age (75 years or more) and time-interval between symptom-onset and start of PCI.

In retrospective study between 1994 - 2001 in France 175 patients presenting with AMI and cardiogenic shock the in-hospital mortality was reported to be 46%. Independent risk factors for increased mortality were presence of TIMI 3 flow, smoking, need of mechanical ventilation. The independent predictors of impaired long term outcome were LVEF < 35% and triple vessel disease.

In REO - SHOCK trial 30 day mortality was 46%. the national registry of myocardial infarction, Jan 1995 - May 2004 in 775 US hospitals reported in hospital mortality of 47.9%. patients randomized to aortic counterpulsation had significantly less reocclusion of infarct-related artery during follow up compared with control patients (8% versus 21%, p=0.05). in addition, there was a significantly lower event rate in patients assigned to aortic counterpulsation in terms of a composite clinical endpoint (death, stroke, reinfarction, need for emergency revascularization with angioplasty or bypass surgery, recurrent ischemia: 13% versus 24%, p<.04). in a prospective observational study of 293, 633 patients from National registry of myocardial infarction, Jan 1995 - may 2004 in 775 US hospitals: cardiogenic shock was present in 2.2% (14%) of patients. There was increase in PPCI rate from 1995 to 2004 54.5%. The in-hospital mortality in 1995 was 48.5% which was reduced in 2004 to 47.9%.

The in-hospital mortality of AMI complicated by cardiogenic shock in this study is high (50%). However, this is lower compared to historical thrombolytic therapy in AMI with cardiogenic shock. Our present study shows that invasive strategy can be alternative mode of treatment compared to thrombolytic therapy despite high mortality even in developing country like Nepal in highly selected patients.

STUDY LIMITATION

This is the only national heart centre in Nepal to start PCI service, hence in the initial phase the total number of routine PCI and primary PCI in cardiogenic shock is small. As this is a retrospective study of a single centre with small number of highly selective patients there is no direct control group with thrombolytic therapy. However, the number of patients admitted with AMI in hospital is small in number and among those only very small number of patients complicated by cardiogenic shock are admitted in hospital.

CONCLUSION

In-hospital mortality in patients with acute myocardial infarction complicated by cardiogenic shock remains high, even with early interventional therapy. Every effort should be made to reduce the incidence of cardiogenic shock. Primary PCI in AMI complicated by cardiogenic shock has lower mortality and improved outcome. High cost, high in-hospital mortality, need for trained manpower are the major limitations.

REFERENCES

1. Hasdai D, Topol EJ, Califf RM, Berger PB, Homes DR Jr. Cardiogenic shock complicating acute coronary syndromes. *Lancet*. 2000;356:749-756.
2. Goldberg RJ, Samad NA, Yarzebski J et al. Temporal trends in cardiogenic shock complicating acute myocardial infarction. *N Engl J Med*. 1993;340:1162-1168.
3. Hasdai D, Holmes DR Jr, Topol EJ, et al. Frequency and clinical outcome of cardiogenic shock during acute myocardial infarction among patients receiving reteplase or alteplase. Results from GUSTO-III Conclusion. *EUR Heart J*. 1999;20:128-135.
4. Sanborn TA, Sleeper LA, Bates ER, et al. Impact of thrombolysis, intra-aortic balloon pump counterpulsation, and their combination in cardiogenic shock complicating acute myocardial infarction: a report from the SHOCK trial registry. *J Am Coll Cardiol*. 2000;36:1123-1129.
5. Silver S, Albertsson P, Aviles FF, et al. Guideline for percutaneous coronary intervention. The task Force for Percutaneous Coronary Intervention of the European Society of Cardiology. *Eur Heart J*. 2005;26:804-847.
6. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, et al. ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention-Summary Article. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). *Circulation*. 2006;113:156-175.
7. Keely EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction, a quantitative review of 23 randomized trials. *Lancet* 2003;361:12-20.
8. Zijlstra F, Hoorntje JC, de Boer B, et al. Long term benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction. *N Engl J Med*. 1999;341:1409-1419.
9. Nunn CM, O'Neill WW, Rothbam D, et al. Long term outcome after primary angioplasty: report from primary angioplasty in myocardial infarction (PAMI-I) trial. *J Am Coll Cardiol*. 1999;33:640-646.
10. Grines CL, Serruys P, O'Neill WW. Fibrinolytic therapy: is it a treatment or past ? *Circulation* 2003;107:2542.
11. Hochman JS, MD, Sleeper LA, White HD, et al. One-year survival following early revascularization for cardiogenic shock. *JAMA*. 2001;285:190-192.
12. Zeymer U, Vogt A, Zahn R, et al. Predictors of in-hospital mortality in 1333 Patients with ST-elevation myocardial infarction complicated by cardiogenic shock treated with primary percutaneous coronary intervention (PAMI-2); Results of the primary PCI registry of the Arbeitsgemeinschaft Leitende Kardiologie Krankenhausärzte (ALHK). *Eur Heart J* 2004;5:327-328;
13. Chodek A, Górnik M, Fajraoui M, et al. Mortality Prognostic Value of cardiogenic shock complicating an acute myocardial infarction and treated by percutaneous coronary intervention. *Int J Cardiol Angeiol*. 2005;54:74-9.
14. Tebbe U, Tebbe U, Webb J, et al. Early abciximab and primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction complicated by cardiogenic shock. Results of the REO-SHOCK trial. *J Invasive Cardiol* 2003;15:385-9.
15. Hochman EM, Liang BS, White CJ, et al Use of aortic balloon pump to improve sustained coronary artery patency during acute myocardial infarction. Results of a randomized trial. The Randomized IABP Study Group. *Circulation*. 1994;90:792-9.
16. Tebbe U, Frey A, Frederick PD, Pasta DJ, Every N, Sichrovsky T, Hochman JS; NRMI Investigators. Trends in management and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock. *JAMA*. 2005;294:448-54.